Tremelimumab: A review of development to date in solid tumors

Immunotherapy

Volumn 5, Issue 3, 2013, Pages 215-229

  Tarhini, Ahmad A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cancer immunotherapy; coinhibitory pathway; CP 675,206; CTLA 4; immune checkpoint; ticilimumab; tremelimumab

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; ALPHA2B INTERFERON; BICALUTAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DENDRITIC CELL VACCINE; EXEMESTANE; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; IPILIMUMAB; MDX 1020; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; SUNITINIB; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLITIS; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EFFECTOR CELL; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; HEADACHE; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; STOMACH CANCER; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; MELANOMA; NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84874623052     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.9     Document Type: Review

References (104)

1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 62(5), 309-335 (2012).
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
3. Finn OJ. Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2012).
4. Disis ML. Immune regulation of cancer. J. Clin. Oncol. 28, 4531-4538 (2010).
5. Block MS, Markovic SN. The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion. Am. J. Immunol. 5, 29-49 (2009).
6. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Cancer 110, 2614-2627 (2007).
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
8. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13, 2-9 (2008).
9. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol. 29, 272-279 (2008).
10. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
11. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1, 220-228 (2001).
12. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717-1725 (2009).
13. Wang X, Zheng C, Giscombe R, Lefvert AK. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand. J. Immunol. 54, 453-458 (2001).
14. Jago CB, Yates J, Olsen Saraiva Câmara N, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol. 136, 463-471 (2004).
15. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int. Immunol. 21, 1105-1111 (2009).
16. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229, 126-144 (2009).
17. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467-477 (2008).
18. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol. Med. 14, 550-559 (2008).
19. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
20. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153-165 (2010).
21. Ménard C, Ghiringhelli F, Roux S et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin. Cancer Res. 14, 5242-5249 (2008).
22. Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106, 2437-2444 (2006).
23. Ribas A, Comin-Anduix B, Economou JS et al. Intratumoral immune cell infiltrates, FOXP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 15, 390-399 (2009).
24. Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int. Arch. Allergy Immunol. 142, 179-189 (2007).
25. Halama N, Zoernig I, Jaeger D. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J. Oncol. 2010, 689893 (2010).
26. Vonka V. Comments on therapeutic cancer vaccines. Immunotherapy 4, 133-135 (2012).
27. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
28. Tarhini AA, Cherian J, Moschos SJ et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 30, 322-328 (2012).
29. Maker A, Phan G, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12, 1005-1016 (2005).
30. Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr. Opin. Immunol. 24, 213-216 (2012).
31. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12, 873-883 (2007).
32. Hanson DC, Canniff PC, Primiano MJ et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc. Amer. Assoc. Cancer Res. 45, Abstract 3802 (2004).
33. Finch G, Hanson D, Wang F, Guyot D, Morton L, Kawabata T. Toxicology studies to support clinical development of tremelimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blocking monoclonal antibody. Presented at: The 47th Annual Meeting of the Society of Toxicology. Seattle, WA, USA, 16-20 March 2008.
34. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23, 8968-8977 (2005).
35. Kang D, Wang E, Wang D, Amantea M, Hsyu P. Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma. J. Clin. Oncol. 27(Suppl. 15), Abstract 3048 (2009).
36. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49, 673-680 (1970).
37. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26, 5950-5956 (2008).
38. Ribas A, Chesney JA, Gordon MS et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J. Transl. Med. 10, 236 (2012).
39. Canniff PC, Donovan CB, Burkwit JJ et al. CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease. Proc. Amer. Assoc. Cancer Res. 45, Abstract 709 (2004).
40. Khan S, Burt DJ, Ralph C, Thistlethwaite FC, Hawkins RE, Elkord E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Life Sci. 138, 85-96 (2010).
41. von Euw E, Chodon T, Attar N et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35 (2009).
42. Comin-Anduix B, Sazegar H, Chodon T et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS ONE 5, e12711 (2010).
43. Pagès F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2012).
44. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
45. Huang RR, Jalil J, Economou JS et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 17, 4101-4109 (2011).
46. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15, 6267-6276 (2009).
47. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
48. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128, 2596-2605 (2008).
49. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999).
50. Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075-1081 (2009).
51. Kirkwood JM, Lorigan P, Hersey P et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16, 1042-1048 (2010).
52. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J. Clin. Oncol. 26, 527-534 (2008).
53. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. 60, 433-442 (2011).
54. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26(Suppl. 15), Abstract LBA9011 (2008).
55. Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622 (2013).
56. Tucker ZC, Laguna BA, Moon E, Singhal S. Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev. 38, 650-661 (2012).
57. Bilusic M, Gulley JL. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol. Immunother. 61, 109-117 (2012).
58. Ribas A. Discussion of CTLA4 and PD-1 blockade for the treatment of advanced melanoma. Presented at: Melanoma/Skin Cancers Track, Oral Abstract Session, 2012 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2012.
59. Tuma RS. Immunotherapies in clinical trials: do they demand different evaluation tools? J. Natl Cancer Inst. 103, 780-781 (2011).
60. Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am. J. Clin. Oncol. 35(6), 606-611 (2012).
61. Healey D, Carlson P, Huang B, Marshall M. Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression. J. Clin. Oncol. 28(Suppl. 15), Abstract 2574 (2010).
62. Bedikian AY, Johnson MM, Warneke CL et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 26, 624-633 (2008).
63. Minor DR, Moore D, Kim C et al. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist 14, 995-1002 (2009).
64. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J. Transl. Med. 6, 62 (2008).
65. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2012).
66. Tarhini AA, Leng S, Moschos SJ et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J. Immunother. 35, 359-366 (2012).
67. Weber JS, Zarour H, Redman B et al. Randomized Phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115, 3944-3954 (2009).
68. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 31, 520-527 (2008).
69. Underhill C, Millward M, Lobb S et al. Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers. J. Clin. Oncol. 27(Suppl. 15), Abstract 3046 (2009).
70. Ralph C, Elkord E, Burt DJ et al. Modulation of lymphocyte regulation for cancer therapy: a Phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin. Cancer Res. 16, 1662-1672 (2010).
71. Calabrò L, Di Giacomo A, Morra A et al. A Phase II study with the anti-CTLA-4 mAb tremelimumab in chemotherapy-resistant advanced malignant mesothelioma: safety, tolerability, clinical and immunologic activity. J. Immunother. 34, 712 (2011).
72. Melero I, Sangro B, Riezu-Boj JI et al. Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: results from a Phase II clinical trial. Presented at: The American Association for Cancer Research Annual Meeting 2012. Chicago, IL, USA, 31 March-4 April 2012 (Abstract 4387).
73. Zatloukal P, Heo DS, Park K et al. Randomized Phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl. 15), Abstract 8071 (2009).
74. Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic t-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28, 3485-3490 (2010).
75. Aglietta M, Barone C, Sawyer M et al. Final toxicity results of a Phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. J. Clin. Oncol. 29(Suppl. 15), Abstract 4081 (2011).
76. Rini BI, Stein M, Shannon P et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758-767 (2011).
77. McNeel DG, Smith HA, Eickhoff JC et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol. Immunother. 61, 1137-1147 (2012).
78. Vonderheide RH, LoRusso PM, Khalil M et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485-3494 (2010).
79. Wallis N, Bulanhagui C, Dorazio P et al. Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer. J. Clin. Oncol. 26(Suppl. 15), Abstract 3040 (2008).
80. Wang E, Kang D, Wang D, Bulanhagui C, Hsyu P. Relationship between pharmacokinetics and safety of tremelimumab in patients with melanoma J. Clin. Oncol. 27(Suppl. 15), Abstract 3049 (2009).
81. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin. Oncol. 37, 499-507 (2010).
82. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043-6053 (2005).
83. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am. J. Roentgenol. 197, W992-W1000 (2011).
84. Bouwhuis MG, ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr. Opin. Oncol. 23, 170-175 (2011).
85. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283-2289 (2006).
86. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012).
87. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872 (2007).
88. Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res. 16, 379-383 (2006).
89. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37, 473-484 (2010).
90. Tarhini AA, Kirkwood JM, Murphy MJ. Diagnostic and prognostic biomarkers and therapetuic targets in melanoma: an overview. In: Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Springer New York, NY, USA, 305-317 (2012).
91. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 117, 104-111 (2005).
92. Marshall M, Ribas A, Huang B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared with chemotherapy in first-line melanoma. J. Clin. Oncol. 28(Suppl. 15), Abstract 2609 (2010).
93. Hamid O, Schmidt H, Nissan A et al. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011).
94. Ji RR, Chasalow S, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019-1031 (2012).
95. Shahabi V, Whitney G, Hamid O et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1-5 (2012).
96. Arkenau H, Kefford R, Long G. Targeting BRAF for patients with melanoma. Br. J. Cancer 104, 392-398 (2010).
97. Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer 116, 1767-1775 (2010).
98. Berman D, Wolchok J, Weber J, Hamid O, O'Day S, Chasalow S. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J. Clin. Oncol. 27(Suppl. 15), Abstract 3020 (2009).
99. Comin-Anduix B, Lee Y, Jalil J et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 6, 22 (2008).
100. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
101. Berry DA. The hazards of endpoints. J. Natl Cancer Inst. 102, 1376-1377 (2010).
102. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
103. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
104. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388-1397 (2010).